Semper Paratus Acquisition Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Surendra K. Ajjarapu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 767 Third Avenue New York City NY United States of America 10017
- IPO Date
- Jan 5, 2022
- CIK
- 0001860871
- Website
- semperparatusspac.com
- Similar Companies
- Business
- Semper Paratus Acquisition Corporation (Nasdaq: LGST) is a blank check company incorporated in the Cayman Islands in 2021 and headquartered at 767 Third Avenue, 38th Floor, New York, New York; the company has no substantial operations and exists principally for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on targets in the transportation, supply chain, and logistics sectors; it offers no products or services beyond its SPAC structure, including redeemable Class A ordinary shares, warrants exercisable at $11.50 per share, and units comprising one share and one-half warrant, which trade under the symbols LGST, LGSTW, and LGSTU respectively. The company targets traditional and next-generation supply chain solutions across end markets globally, leveraging its management team's expertise in transportation and logistics; geographic operations emphasize opportunities worldwide, particularly in areas disrupted by supply chain challenges; its sponsor, Semper Paratus Sponsor LLC, holds founder shares convertible to Class A ordinary shares upon a business combination. Recent developments include a definitive merger agreement with Tevogen Bio Inc., a clinical-stage immunotherapy company developing T cell therapies for infectious diseases and cancers, announced in July 2023; Semper Paratus shareholders approved the transaction on January 31, 2024, with an anticipated Nasdaq listing of the combined entity under a new ticker following closing, originally expected in Q1 2024 though subject to subsequent extensions of the SPAC's combination deadline through December 2024; the deal reflects a strategic shift from initial transportation focus to biotechnology, positioning the post-combination company for growth in life sciences amid ongoing regulatory and shareholder processes.
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio
Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination
Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
Citadel Advisors LLC's Recent Transaction in Semper Paratus Acquisition Corp